drugset

drugset / Trial / NCT06161259

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

NCT06161259 ↗

Phase 1 Completed 24 enrolled Guangdong Raynovent Biotech Co., Ltd

Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir(RAY1216)

Timeline

Start: 2023-09-14
Primary completion: 2023-10-01
Completion: 2023-10-07

Publications

Li C, Mai J, Wu M, Zhang H, Li X, Li H, Li Y, Ding Y. Single-dose tolerability and pharmacokinetics of leritrelvir in Chinese patients with hepatic impairment and healthy matched controls. Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0137724. doi: 10.1128/aac.01377-24. Epub 2024 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leritrelvir	Unknown	400 mg	Oral

Indications

No indication recorded.